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Disease Burden 
• The number one preventable cause of death in 
Canada (Health and Welfare, Canada 2000) 
• 47,000 smoking related deaths per year (1998, 
Health Canada) 
• 1 in 2 smokers die from a smoking related illness 
• 44% of consumption by the mentally ill 
 
 
             Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' 
observations on male British doctors. BMJ. 2004 
            Lasser K, Boyd JW, Woolhandler S et al. (2000), Smoking and mental illness. A 
population-based prevalence study. JAMA 
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Program Description 
• The Tobacco Dependence Clinic (TDC) is a program 
that provides behavioural counselling and up to 26 
weeks of no-cost pharmacotherapy for clients through 
VCH Addiction Services 
 
• Program is run with a team of nurses, counsellors, 
respiratory therapists, and a physician. 
 
• Currently in 7 Addictions services located in community 
health centres in Vancouver. 
Intake 
Eligibility: 
 
• 19 years or older 
• Tobacco dependent 
• Have a history of substance use disorder and/or mental 
illness 
• Financially disadvantaged 
 
8 Week Structured Group 
 
 
Quitting smoking is a process and not  
an event 
Stages of Change 
• Using harm reduction, skill development, and confidence 
building we move people to action 
 
• Precontemplation – no desire for change 
• Contemplation – aware of a need to make change but still ambivalent 
• Preparation – ready to take small steps and to plan 
• Action – making change, building capacity for change, improved self-efficacy 
• Maintenance – sustaining change 
• Lapse/relapse  
(Miller, W., Rollinick, S., 1991) 
Phases of Treatment 
• Phase 1: engagement in the process – weeks 1-2 
 
• Phase 2: planning for change – weeks 3-4 
 
• Phase 3: sustaining change – weeks 5-8 
Engaging in Change, Weeks 1-2 
Get individuals to buy in, make small steps 
What do we do: 
• Decisional balance – acknowledge the past role of 
smoking, address concerns about quitting, emphasize 
the plusses of being smoke free 
• Tally daily smoking patterns 
• Identify situational, emotional, and cognitive triggers 
• Identify basic coping strategies for triggers (ie. Distraction, deep 
breathing, etc) 
Making the Plan, Weeks 3-4 
Outlining what change will look like 
 
What do we do: 
• Use a 2-month calendar to outline weekly 
smoking reduction, optional quit date, weekly 
rewards and self-care 
• Discuss signs and symptoms of withdrawal 
Sustaining Change, Weeks 5-8 
Filling in the void left by quitting smoking 
 
What do we do: 
• Discuss emotions with an emphasis on stress 
management 
• Physical health and wellness (ie. Weight gain) 
• Reinforce positive thinking and positive change 
• Identifying risk, tools for dealing with slips, relapse 
prevention 
Outcome Evaluation 
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Sample Characteristics (N = 739) 
Mean Stand. Dev. 
Age of participant (years) 
 
47.2 11.4 
Age at smoking initiation (years) 
 
14.9 5.2 
Importance of quitting (scale of 0 ‘low’ to 10 ‘high’) 9.0 1.3 
Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’) 
 
7.3 2.3 
Number of cigarettes smoked per day 
 
20.6 10.8 
Fagerstrom Test for Nicotine Dependence  
(scale of 0 ‘low’ to 10 ‘high’) 
 
6.0 2.1 
CO level at baseline (ppm) 20.1 12.4 
Sample for Outcomes Assessment  
739 
Completed intake and orientation 
 
(Sept 2007 to March 2011) 
240 
•Not engaged in the program (i.e., had 
two or less contacts with the program) 
•No gender reported 540 
Intent to treat 
139 
Program non-completers 
406 
program completers 
Smoking cessation: 7-day point-prevalence of abstinence at end of treatment  
(i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels 
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Smoking Cessation* Outcomes at end-of-treatment  
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Multivariate preditorsab of smoking cessation at end of 
treatment (i.e., within 26 weeks) (n = 388) 
Predictors Odds Ratio 95%CI 
History of Psychiatric Disorder 
None (reference) 
Mood disorder 
Anxiety disorder 
Psychotic disorder 
 
1.0 
.78 
.45* 
.89 
 
- 
.45-1.35 
.22-.94 
.35-2.35 
FTND at baseline .88* .70-1.00 
       CO level at baseline 
.98* .96-1.00 
       Number of Visits to the TDC 
1.09*** 1.05-1.12 
a. Only variables which were significantly predictive of smoking cessation in the final multivariate 
model are shown.  
b. Hosmer-Lemeshow goodness-of-fit: χ2= 8.02 (DF=8), p=.432 
* = p <.05, ** = p <.001, *** = p <.001 
Summary of Key Findings 
• Smoking abstinence at end of program: 
 
– Intent to treat analysis: 31%(167/540)   
– Among program completers: 41%(167/406)  
 
 
• Significant predictors of abstinence: 
– Having a history of an anxiety disorder is predictive of being less 
likely to quit smoking when compared to having no history of a 
psychiatric disorder.   
– Having a lower CO level at program enrolment was a significant 
predictor of being more likely to quit  
– Attending the TDC program for a longer duration was a significant 
predictor of being more likely to quit. 
 
 
Conclusions 
 
• The Tobacco Dependence Clinic provides an innovative 
model of tailored tobacco dependence treatment which 
combines behavioural counselling with no-cost NRT for 
individuals with a history of substance use and/or 
psychiatric disorders. 
 
• With intensive tobacco dependence treatment provided 
within addictions services, individuals with a history of 
substance use and/or psychiatric disorders are able to 
achieve smoking abstinence. 
 
 
 

